Elevance said it was “surprised and disappointed” by a recent CMS sanction threat, which would suspend enrollment in Medicare Advantage prescription drug plans, CFO Mark Kaye said March 10 at the Barclays 28th Annual Global Healthcare Conference in Miami.
The executive claimed Elevance flagged provider-submitted diagnosis codes and shared information with CMS “in good faith.” ARTICLE